EphA2、EphrinA 1在膀胱癌组织中的表达及其临床意义

Expressions of EphA2 and EphrinA1 in bladder carcinomas and their clinical significance

目的 探讨膀胱癌组织中EphA2、EphrinA1的表达及其与临床病理因素的关系,以及联合检测在膀胱癌预后中的意义.方法 采用S-P免疫组织化学技术检测75例膀胱癌切除术后的组织石蜡标本中EphA2和EphrinA1的表达,并结合临床病理因素进行分析.结果 （1）膀胱癌组织中EphA2和EphrinA1的阳性表达率分别为61.3%（46/75）和46.7%（35/75）.（2）EphA2的阳性表达率与膀胱癌患者的性别、年龄、病理类型均无显著相关性（P＞0.05） 而与肿瘤大小、有无淋巴结转移及TNM分期显著相关（P＜0.05）.（3）EphrinA1的阳性表达率与膀胱癌患者的性别、年龄、病理类型、TNM分期均无显著相关性（P＞0.05） 而与肿瘤大小、有无淋巴结转移显著相关（P＜0.05）.（4）EphA2的阳性表达率与EphrinA1的阳性表达率显著相关（P＜0.05）.结论 EphA2和EphrinA1与膀胱癌的发生、发展有关,联合检测有助于客观评估膀胱癌的生物学行为,可用来指导临床用药和判断预后.

Objective To investigate the expressions of EphA2 and EphrinA1 in bladder carcinomas and their clinical significance. Method The expressions of EphA2 and EphrinA1 were detected on bladder carcinomas （75 cases ） by immunohistochemistry S-P method. Results （ 1 ） The positive rates of expression of EphA2 and EphrinA1 were 61.3%（46/75） and 46.7%（35/75） respectively. （2） The expression of EphA2 was related to tumor size, lymphatic metastasis and TNM staging（P〈 0.05）,but not to gender,age and pathology type （P 〉 0.05 ）. （ 3 ）The expression of EphrinA1 was related to tumor size and lymphatic metastasis （P 〈 0.05 ）, but not to gender, age, pathology type and TNM staging （P 〉 0.05 ）. （4）There was significantly positive correlation between the expression of EphA2 and EphrinA1 （P 〈 0.05）.Conclusions EphA2 and EphrinA1 are related to the occurrence and development of bladder carcinoma.The combined detection of EphA2 and EphrinA1 can help to predict the clinical and pathologic characteristics of bladder carcinoma. It is an important index to assist treatment, they are predictive factors for bladder carcinoma.